Healthcare facilities such as the Hyperbaric Medical Solutions is taking extra preventive steps to mitigate the risks of the coronavirus pandemic to ensure all patients are offered clean and safe environments. Stakeholders in the radiation proctitis market are increasing efforts to boost the availability for hyperbaric oxygen therapy (HBOT), which is being associated with enhancing the immune system in the wake of the COVID-19 outbreak.
Companies in the radiation proctitis market are maintaining steady supply of intravenous (IV) vitamin drips, which help to strengthen the immunity of patients and help in detoxification. However, a slowdown in the global economy may have affected revenue collections in healthcare facilities. Hence, healthcare companies should adopt flexible business strategies, and team up with their stakeholders in the value chain to manage investments and product launches.
HBOT is emerging as the gold standard for treating radiation toxicity. However, this treatment is being associated with side effects such as transient myopia, fatigue, and barotrauma. Moreover, patients with severe complaints refrain from participating and even opt out of randomized controlled trials. Hence, companies in the radiation proctitis market are collaborating with research institutes to create alternative trials design in order to overcome the issues in trials within cohorts design.
The approval of the U.S.-based FDA (Food & Drug Association) for HBOT is creating incremental opportunities for companies in the radiation proctitis market. This explains why the market is expected to reach US$ 748.5 Mn by 2030.
Improvements in radiotherapy techniques are enabling superior delivery of radiation doses, and have the potential to easily reduce cases of both chronic and acute proctitis. Despite these advancements, the radiation proctitis market is projected to register a favorable CAGR of ~7% during the assessment period, owing to a high prevalence of radiation toxicity.
Healthcare providers in the radiation proctitis market are gaining proficiency iron substitution therapies. Manufacturers are boosting their output capacities in topical corticosteroids, sucralfate injections, and increasing R&D in antidiarrheal therapies, since the latter is gaining popularity as an aggressive means for patient care.
Apart from oral therapies, companies and healthcare providers in the radiation proctitis market are offering remedial laser techniques in cases of continuous rectal bleeding. Clinicians are attempting formaldehyde administration before the surgical therapy. Healthcare professionals are conducting a descending or transverse colostomy for patients when surgery is required. Companies in the radiation proctitis market are increasing the availability of intraperitoneal injections of formalin.
Novel methods of cold therapy and radiofrequency ablation (RFA) are grabbing the attention of healthcare providers. Colostomy is gaining prominence as an effective and safe procedure for treating rectal ulcer of chronic radiation proctitis patients. Colostomy helps to control rectal bleeding and effectively relieve pain in patients.
The high prevalence of hemorrhagic radiation proctitis is acting as a key driver for the expansion of the radiation proctitis market. However, the lack of consensus for the management of hemorrhagic radiation proctitis is likely to inhibit market growth. Despite the challenges, clinicians are adopting rectal resection as an available option for hemorrhagic radiation proctitis management.
Healthcare companies in the radiation proctitis market are increasing their R&D in prostaglandins that aid in the healing of inflammation and wounds. This has led to the popularity of misoprostol, which is found to be efficacious in treating complications that arise in patients with prostate cancer that receive radiation therapy. Misoprostol rectal suppositories are being highly publicized for reducing the complications associated with acute and chronic radiation proctitis.
Analysts’ Viewpoint
Healthcare providers are providing uncompromised care services to radiation proctitis patients despite reduced hospital and clinical visits during the ongoing COVID-19 outbreak. Even as the National Comprehensive Cancer Network (NCCN) is setting guidelines for the Radiation Therapy Compendium™ Development, companies and healthcare providers are increasing efforts to gain proficiency in HBOT. However, HBOT is associated with oxygen toxicity and seizures. Hence, companies and healthcare professionals in the radiation proctitis market should encourage patients to participate in controlled trials and alternative trial design to improve medical outcomes. As such, manufacturers are increasing their focus in stool softeners and treatments that heal tissues in order to minimize patient complications.
Radiation proctitis market is expected to reach US$ 748.5 Mn by 2030
Radiation proctitis market is projected to expand at a CAGR of ~7% from 2020 to 2030
Radiation proctitis market is driven by increase in incidence of urinary diseases
The acute radiation proctitis segment dominated the global radiation proctitis market, and the trend is projected to continue during the forecast period
Key players in the global radiation proctitis market are Allergan plc, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Pfizer, Inc., Mylan, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiation Proctitis market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Radiation Proctitis Market Analysis and Forecast, 2018–2030
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Prevalence of Urinary Incontinence, by Region
5.2. Key Industry Events
5.3. Regulatory Scenario
5.4. Technological Advancements
5.5. Key Success Factors of Top Players
6. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication
6.1. Introduction & Definition
6.2. Global Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
6.2.1. Acute Radiation Proctitis
6.2.2. Chronic Radiation Proctitis
6.3. Global Radiation Proctitis Market Attractiveness Analysis, by Indication
7. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy
7.1. Introduction & Definition
7.2. Global Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
7.2.1. Oral Therapy
7.2.1.1. Antidiarrheals
7.2.1.2. Anti-inflammatory Agents
7.2.1.3. Others
7.2.2. Ablative Procedures
7.2.3. Hyperbaric Oxygen Therapy
7.2.4. Formalin
7.2.5. Surgery
8. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Region
8.1. Introduction
8.2. Radiation Proctitis Market Value Forecast, by Region, 2018–2030
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Radiation Proctitis Market Attractiveness Analysis, by Region
9. North America Radiation Proctitis Market Analysis and Forecast
9.1. Introduction
9.2. North America Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
9.2.1. Acute Radiation Proctitis
9.2.2. Chronic Radiation Proctitis
9.3. North America Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
9.3.1. Oral Therapy
9.3.1.1. Antidiarrheals
9.3.1.2. Anti-inflammatory Agents
9.3.1.3. Others
9.3.2. Ablative Procedures
9.3.3. Hyperbaric Oxygen Therapy
9.3.4. Formalin
9.3.5. Surgery
9.4. North America Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
9.4.1. U.S.
9.4.2. Canada
9.5. North America Radiation Proctitis Market Attractiveness Analysis
9.5.1. By Indication
9.5.2. By Therapy
9.5.3. By Country/Sub-region
10. Europe Radiation Proctitis Market Analysis and Forecast
10.1. Introduction
10.2. Europe Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
10.2.1. Acute Radiation Proctitis
10.2.2. Chronic Radiation Proctitis
10.3. Europe Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
10.3.1. Oral Therapy
10.3.1.1. Antidiarrheals
10.3.1.2. Anti-inflammatory Agents
10.3.1.3. Others
10.3.2. Ablative Procedures
10.3.3. Hyperbaric Oxygen Therapy
10.3.4. Formalin
10.3.5. Surgery
10.4. Europe Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Radiation Proctitis Market Attractiveness Analysis
10.5.1. By Indication
10.5.2. By Therapy
10.5.3. By Country/Sub-region
11. Asia Pacific Radiation Proctitis Market Analysis and Forecast
11.1. Introduction
11.2. Asia Pacific Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
11.2.1. Acute Radiation Proctitis
11.2.2. Chronic Radiation Proctitis
11.3. Asia Pacific Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
11.3.1. Oral Therapy
11.3.1.1. Antidiarrheals
11.3.1.2. Anti-inflammatory Agents
11.3.1.3. Others
11.3.2. Ablative Procedures
11.3.3. Hyperbaric Oxygen Therapy
11.3.4. Formalin
11.3.5. Surgery
11.4. Asia Pacific Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Radiation Proctitis Market Attractiveness Analysis
11.5.1. By Indication
11.5.2. By Therapy
11.5.3. By Country/Sub-region
12. Latin America Radiation Proctitis Market Analysis and Forecast
12.1. Introduction
12.2. Latin America Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
12.2.1. Acute Radiation Proctitis
12.2.2. Chronic Radiation Proctitis
12.3. Latin America Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
12.3.1. Oral Therapy
12.3.2. Ablative Procedures
12.3.3. Hyperbaric Oxygen Therapy
12.3.4. Formalin
12.3.5. Surgery
12.4. Latin America Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Radiation Proctitis Market Attractiveness Analysis
12.5.1. By Indication
12.5.2. By Therapy
12.5.3. By Country/Sub-region
13. Middle East & Africa Radiation Proctitis Market Analysis and Forecast
13.1. Introduction
13.2. Middle East & Africa Radiation Proctitis Market Value Forecast, by Indication, 2018–2030
13.2.1. Acute Radiation Proctitis
13.2.2. Chronic Radiation Proctitis
13.3. Middle East & Africa Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030
13.3.1. Oral Therapy
13.3.1.1. Antidiarrheals
13.3.1.2. Anti-inflammatory Agents
13.3.1.3. Others
13.3.2. Ablative Procedures
13.3.3. Hyperbaric Oxygen Therapy
13.3.4. Formalin
13.3.5. Surgery
13.4. Middle East & Africa Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Radiation Proctitis Market Attractiveness Analysis
13.5.1. By Indication
13.5.2. By Therapy
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Global Radiation Proctitis Market Share Analysis, by Company, 2019
14.2. Company Profiles
14.2.1. Allergan plc
14.2.1.1. Company Description
14.2.1.2. Business Overview
14.2.1.3. Financial Overview
14.2.1.4. Strategic Overview
14.2.1.5. SWOT Analysis
14.2.2. Teva Pharmaceutical Industries Ltd.
14.2.2.1. Company Description
14.2.2.2. Business Overview
14.2.2.3. Financial Overview
14.2.2.4. Strategic Overview
14.2.2.5. SWOT Analysis
14.2.3. Amneal Pharmaceuticals, Inc.
14.2.3.1. Company Description
14.2.3.2. Business Overview
14.2.3.3. Financial Overview
14.2.3.4. Strategic Overview
14.2.3.5. SWOT Analysis
14.2.4. Pfizer, Inc.
14.2.4.1. Company Description
14.2.4.2. Business Overview
14.2.4.3. Financial Overview
14.2.4.4. Strategic Overview
14.2.4.5. SWOT Analysis
14.2.5. Mylan, Inc., (Viatris)
14.2.5.1. Company Description
14.2.5.2. Business Overview
14.2.5.3. Financial Overview
14.2.5.4. Strategic Overview
14.2.5.5. SWOT Analysis
14.2.6. Sanofi
14.2.6.1. Company Description
14.2.6.2. Business Overview
14.2.6.3. Financial Overview
14.2.6.4. Strategic Overview
14.2.6.5. SWOT Analysis
14.2.7. Johnson & Johnson (Johnson & Johnson Consumer, Inc.)
14.2.7.1. Company Description
14.2.7.2. Business Overview
14.2.7.3. Financial Overview
14.2.7.4. Strategic Overview
14.2.7.5. SWOT Analysis
14.2.8. Sun Pharmaceutical Industries Ltd.
14.2.8.1. Company Description
14.2.8.2. Business Overview
14.2.8.3. Financial Overview
14.2.8.4. Strategic Overview
14.2.8.5. SWOT Analysis
14.2.9. Environmental Tectonics Corporation
14.2.9.1. Company Description
14.2.9.2. Business Overview
14.2.9.3. Financial Overview
14.2.9.4. Strategic Overview
14.2.9.5. SWOT Analysis
14.2.10. Sechrist Industries, Inc.
14.2.10.1. Company Description
14.2.10.2. Business Overview
14.2.10.3. Financial Overview
14.2.10.4. Strategic Overview
14.2.10.5. SWOT Analysis
List of Tables
Table 01: Radiation Proctitis: Clinical Trial Pipeline Analysis (1/2)
Table 02: Radiation Proctitis: Clinical Trial Pipeline Analysis (2/2)
Table 03: Estimated Number of Patients with Radiation Proctitis, by Key indications, by Key Countries 2020 (1/2)
Table 04: Estimated Number of Patients with Radiation Proctitis, by Key indications, by Key Countries 2020 (2/2)
Table 05: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 06: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030
Table 07: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030
Table 08: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 09: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 10: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 11: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030
Table 12: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030
Table 13: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 15: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030
Table 16: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030
Table 17: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 18: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 19: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030
Table 20: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030
Table 21: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 22: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 23: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030
Table 24: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030
Table 25: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030
Table 27: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030
Table 28: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030
List of Figures
Figure 01: Global Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Radiation Proctitis Market Value Share, by Indication, 2019
Figure 03: Global Radiation Proctitis Market Value Share, by Therapy, 2019
Figure 04: Global Radiation Proctitis Market Value Share, by Region, 2019
Figure 05: Global Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030
Figure 06: Global Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030
Figure 07: Global Radiation Proctitis Market Value (US$ Mn), by Acute Radiation Proctitis, 2018–2030
Figure 08: Global Radiation Proctitis Market Value (US$ Mn), by Chronic Radiation Proctitis, 2018–2030
Figure 09: Global Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030
Figure 10: Global Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030
Figure 11: Global Radiation Proctitis Market Value (US$ Mn), by Oral Therapy, 2018–2030
Figure 12: Global Radiation Proctitis Market Value (US$ Mn), by Ablative Procedures, 2018–2030
Figure 13: Global Radiation Proctitis Market Value (US$ Mn), by Hyperbaric Oxygen Therapy, 2018–2030
Figure 14: Global Radiation Proctitis Market Value (US$ Mn), by Formalin, 2018–2030
Figure 15: Global Radiation Proctitis Market Value (US$ Mn), by Surgery, 2018–2030
Figure 16: Global Radiation Proctitis Market Value Share Analysis, by Region, 2019 and 2030
Figure 17: Global Radiation Proctitis Market Attractiveness Analysis, by Region, 2020–2030
Figure 18: North America Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030
Figure 19: North America Radiation Proctitis Market Value Share Analysis, by Country, 2019 and 2030
Figure 20: North America Radiation Proctitis Market Attractiveness Analysis, by Country, 2020–2030
Figure 21: North America Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030
Figure 22: North America Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030
Figure 23: North America Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030
Figure 24: North America Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030
Figure 25: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030
Figure 26: Europe Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 27: Europe Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 28: Europe Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030
Figure 29: Europe Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030
Figure 30: Europe Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030
Figure 31: Europe Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030
Figure 32: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030
Figure 33: Asia Pacific Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 34: Asia Pacific Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 35: Asia Pacific Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030
Figure 36: Asia Pacific Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030
Figure 37: Asia Pacific Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030
Figure 38: Asia Pacific Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030
Figure 39: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030
Figure 40: Latin America Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 41: Latin America Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 42: Latin America Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030
Figure 43: Latin America Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030
Figure 44: Latin America Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030
Figure 45: Latin America Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030
Figure 46: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030
Figure 47: Middle East & Africa Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
Figure 48: Middle East & Africa Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 49: Middle East & Africa Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030
Figure 50: Middle East & Africa Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030
Figure 51: Middle East & Africa Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030
Figure 52: Middle East & Africa Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Radiation Proctitis Market
